{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T23:13:24Z","timestamp":1793056404421,"version":"4.5.0"},"reference-count":74,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T00:00:00Z","timestamp":1755734400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Metastasis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>We previously identified three molecular subtypes of prostate cancer (PC) bone metastases, MetA-C, with MetB linked to poor prognosis after androgen deprivation therapy (ADT). This study analyzed epithelial and stromal markers using immunohistochemistry, focusing on their relationship to MetA-C subtypes, spatial heterogeneities, and clinical outcomes after ADT. High tumor proliferation and low PSA expression were associated with MetB and poor outcomes after ADT. Most metastases contained tumor epithelial subclones with different morphologies. In the metastasis stroma, blood vessels and fibroblast-like cells expressed smooth muscle actin (SMA), platelet-derived growth factor \u03b2, stroma-derived factor 1 (SDF1), periostin (POSTN), and decorin (DCN). Compared to each other, MetB metastases had higher SMA and ERG\u2009+\u2009endothelial cell densities, while MetA cases showed higher SDF1 and DCN levels. Accordingly, high POSTN and ERG\u2009+\u2009densities were associated with poor outcomes after ADT, whereas high DCN indicated favorable prognosis. Low levels of AR-positive stromal cells were linked to poor outcomes. Macrophage and T-lymphocyte densities showed no significant associations with metastases subtypes or outcome. Two stroma subtypes were identified: subtype 1 with higher bone content, lower vessel density, MetA-enrichment and better prognosis compared to subtype 2 that exhibited higher tumor proliferation and lower PSA expression. Most metastases contained regions of both stroma subtypes.<\/jats:p>","DOI":"10.1007\/s10585-025-10365-y","type":"journal-article","created":{"date-parts":[[2025,8,21]],"date-time":"2025-08-21T18:25:02Z","timestamp":1755800702000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Morphological heterogeneities in prostate cancer bone metastases are related to molecular subtypes and prognosis"],"prefix":"10.1007","volume":"42","author":[{"given":"Sofia","family":"Halin Bergstr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julius","family":"Semenas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Nordstrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elin","family":"Thysell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"W\u00e4nman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sead","family":"Crnalic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Widmark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Thellenberg-Karlsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Andersson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Gidlund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Lundholm","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Wel\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Josefsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pernilla","family":"Wikstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"Bergh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,21]]},"reference":[{"issue":"2","key":"10365_CR1","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.eururo.2020.09.046","volume":"79","author":"P Cornford","year":"2021","unstructured":"Cornford P et al (2021) EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer. Part II-2020 update: treatment of relapsing and metastatic prostate Cancer. Eur Urol 79(2):263\u2013282","journal-title":"Eur Urol"},{"issue":"3","key":"10365_CR2","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1016\/j.neo.2016.01.007","volume":"18","author":"SH Bergstrom","year":"2016","unstructured":"Bergstrom SH, Rudolfsson SH, Bergh A (2016) Rat prostate tumor cells progress in the bone microenvironment to a highly aggressive phenotype. Neoplasia 18(3):152\u2013161","journal-title":"Neoplasia"},{"issue":"4","key":"10365_CR3","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1677\/ERC-10-0059","volume":"17","author":"S Crnalic","year":"2010","unstructured":"Crnalic S et al (2010) Nuclear androgen receptor staining in bone metastases is related to a poor outcome in prostate cancer patients. Endocr-Relat Cancer 17(4):885\u2013895","journal-title":"Endocr-Relat Cancer"},{"issue":"4","key":"10365_CR4","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1002\/pros.20139","volume":"62","author":"N Ohlson","year":"2005","unstructured":"Ohlson N et al (2005) Cell proliferation and apoptosis in prostate tumors and adjacent non-malignant prostate tissue in patients at different time-points after castration treatment. Prostate 62(4):307\u2013315","journal-title":"Prostate"},{"issue":"21","key":"10365_CR5","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1158\/1078-0432.CCR-18-1229","volume":"24","author":"D Iglesias-Gato","year":"2018","unstructured":"Iglesias-Gato D et al (2018) The proteome of prostate cancer bone metastasis reveals heterogeneity with prognostic implications. Clin Cancer Res 24(21):5433\u20135444","journal-title":"Clin Cancer Res"},{"issue":"4","key":"10365_CR6","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1002\/1878-0261.13158","volume":"16","author":"E Thysell","year":"2022","unstructured":"Thysell E et al (2022) Clinical and biological relevance of the transcriptomic-based prostate cancer metastasis subtypes MetA-C. Mol Oncol 16(4):846\u2013859","journal-title":"Mol Oncol"},{"issue":"8","key":"10365_CR7","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1002\/1878-0261.12526","volume":"13","author":"E Thysell","year":"2019","unstructured":"Thysell E et al (2019) Gene expression profiles define molecular subtypes of prostate cancer bone metastases with different outcomes and morphology traceable back to the primary tumor. Mol Oncol 13(8):1763\u20131777","journal-title":"Mol Oncol"},{"key":"10365_CR8","doi-asserted-by":"crossref","unstructured":"Wikstrom P et al (2022) Epithelial and stromal characteristics of primary tumors predict the bone metastatic subtype of prostate Cancer and patient survival after Androgen-Deprivation therapy. Cancers (Basel) 1421","DOI":"10.3390\/cancers14215195"},{"issue":"23","key":"10365_CR9","doi-asserted-by":"publisher","first-page":"11428","DOI":"10.1073\/pnas.1902651116","volume":"116","author":"W Abida","year":"2019","unstructured":"Abida W et al (2019) Genomic correlates of clinical outcome in advanced prostate cancer. Proc Natl Acad Sci USA 116(23):11428\u201311436","journal-title":"Proc Natl Acad Sci USA"},{"issue":"4","key":"10365_CR10","doi-asserted-by":"publisher","first-page":"e19059","DOI":"10.1371\/journal.pone.0019059","volume":"6","author":"E Hornberg","year":"2011","unstructured":"Hornberg E et al (2011) Expression of androgen receptor splice variants in prostate Cancer bone metastases is associated with castration-resistance and short survival. PLoS ONE 6(4):e19059","journal-title":"PLoS ONE"},{"issue":"10","key":"10365_CR11","doi-asserted-by":"publisher","first-page":"4492","DOI":"10.1172\/JCI128212","volume":"129","author":"MP Labrecque","year":"2019","unstructured":"Labrecque MP et al (2019) Molecular profiling stratifies diverse phenotypes of treatment-refractory metastatic castration-resistant prostate cancer. J Clin Invest 129(10):4492\u20134505","journal-title":"J Clin Invest"},{"issue":"4","key":"10365_CR12","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.3390\/ijms19041223","volume":"19","author":"A Nordstrand","year":"2018","unstructured":"Nordstrand A et al (2018) Bone cell activity in clinical prostate cancer bone metastasis and its inverse relation to tumor cell androgen receptor activity. Int J Mol Sci 19(4):1223","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10365_CR13","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1016\/j.cell.2018.10.019","volume":"175","author":"DA Quigley","year":"2018","unstructured":"Quigley DA et al (2018) Genomic hallmarks and structural variation in metastatic prostate cancer. Cell 175(3):889","journal-title":"Cell"},{"issue":"3","key":"10365_CR14","doi-asserted-by":"publisher","first-page":"1154","DOI":"10.1016\/j.juro.2008.04.140","volume":"180","author":"MP Roudier","year":"2008","unstructured":"Roudier MP et al (2008) Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol 180(3):1154\u20131160","journal-title":"J Urol"},{"issue":"5","key":"10365_CR15","doi-asserted-by":"publisher","first-page":"E147","DOI":"10.1016\/j.eururo.2017.07.043","volume":"72","author":"EB Ylitalo","year":"2017","unstructured":"Ylitalo EB et al (2017) Subgroups of Castration-resistant prostate Cancer bone metastases defined through an inverse relationship between androgen receptor activity and immune response (71, Pg 776, 2017). Eur Urol 72(5):E147\u2013E","journal-title":"Eur Urol"},{"issue":"1","key":"10365_CR16","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1186\/s13148-021-01119-0","volume":"13","author":"EB Ylitalo","year":"2021","unstructured":"Ylitalo EB et al (2021) A novel DNA methylation signature is associated with androgen receptor activity and patient prognosis in bone metastatic prostate cancer. Clin Epigenetics 13(1):133","journal-title":"Clin Epigenetics"},{"issue":"17","key":"10365_CR17","doi-asserted-by":"publisher","first-page":"4948","DOI":"10.1158\/0008-5472.CAN-16-0902","volume":"76","author":"S You","year":"2016","unstructured":"You S et al (2016) Integrated classification of prostate Cancer reveals a novel luminal subtype with poor outcome. Cancer Res 76(17):4948\u20134958","journal-title":"Cancer Res"},{"issue":"12","key":"10365_CR18","doi-asserted-by":"publisher","first-page":"1663","DOI":"10.1001\/jamaoncol.2017.0751","volume":"3","author":"SG Zhao","year":"2017","unstructured":"Zhao SG et al (2017) Associations of luminal and basal subtyping of prostate cancer with prognosis and response to androgen deprivation therapy. JAMA Oncol 3(12):1663\u20131672","journal-title":"JAMA Oncol"},{"key":"10365_CR19","doi-asserted-by":"crossref","unstructured":"Bedeschi M et al (2023) Cancer-associated fibroblast: role in prostate cancer progression to metastatic disease and therapeutic resistance. Cells 12:5","DOI":"10.3390\/cells12050802"},{"issue":"1","key":"10365_CR20","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41698-022-00272-w","volume":"6","author":"R Ge","year":"2022","unstructured":"Ge R, Wang Z, Cheng L (2022) Tumor microenvironment heterogeneity an important mediator of prostate cancer progression and therapeutic resistance. NPJ Precis Oncol 6(1):31","journal-title":"NPJ Precis Oncol"},{"issue":"2","key":"10365_CR21","doi-asserted-by":"publisher","first-page":"531","DOI":"10.3390\/cancers4020531","volume":"4","author":"C Hagglof","year":"2012","unstructured":"Hagglof C, Bergh A (2012) The stroma-a key regulator in prostate function and malignancy. Cancers (Basel) 4(2):531\u2013548","journal-title":"Cancers (Basel)"},{"issue":"8","key":"10365_CR22","doi-asserted-by":"publisher","first-page":"a030510","DOI":"10.1101\/cshperspect.a030510","volume":"8","author":"C Levesque","year":"2018","unstructured":"Levesque C, Nelson PS (2018) Cellular constituents of the prostate stroma: key contributors to prostate cancer progression and therapy resistance. Cold Spring Harb Perspect Med 8(8):a030510","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10365_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3390\/biom13010067","volume":"13","author":"JS Owen","year":"2022","unstructured":"Owen JS, Clayton A, Pearson HB (2022) Cancer-Associated fibroblast heterogeneity, activation and function: implications for prostate cancer. Biomolecules 13:1","journal-title":"Biomolecules"},{"issue":"6","key":"10365_CR24","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1038\/s41416-022-02085-x","volume":"128","author":"F Pederzoli","year":"2023","unstructured":"Pederzoli F et al (2023) Stromal cells in prostate cancer pathobiology: Friends or foes? Br J Cancer 128(6):930\u2013939","journal-title":"Br J Cancer"},{"issue":"7","key":"10365_CR25","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.cell.2019.04.040","volume":"177","author":"N Baryawno","year":"2019","unstructured":"Baryawno N et al (2019) A cellular taxonomy of the bone marrow stroma in homeostasis and leukemia. Cell 177(7):1915\u20131932 e16","journal-title":"Cell"},{"issue":"11","key":"10365_CR26","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.ccell.2021.09.005","volume":"39","author":"Y Kfoury","year":"2021","unstructured":"Kfoury Y et al (2021) Human prostate cancer bone metastases have an actionable immunosuppressive microenvironment. Cancer Cell 39(11):1464\u201378e8","journal-title":"Cancer Cell"},{"issue":"2","key":"10365_CR27","doi-asserted-by":"publisher","first-page":"e86824","DOI":"10.1371\/journal.pone.0086824","volume":"9","author":"C Hagglof","year":"2014","unstructured":"Hagglof C et al (2014) TMPRSS2-ERG expression predicts prostate cancer survival and associates with stromal biomarkers. PLoS ONE 9(2):e86824","journal-title":"PLoS ONE"},{"issue":"10","key":"10365_CR28","doi-asserted-by":"publisher","first-page":"3493","DOI":"10.1210\/jcem.82.10.4319","volume":"82","author":"EO Abu","year":"1997","unstructured":"Abu EO et al (1997) The localization of androgen receptors in human bone. J Clin Endocrinol Metab 82(10):3493\u20133497","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10365_CR29","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/1096-9896(0000)9999:9999<::AID-PATH803>3.0.CO;2-W","volume":"193","author":"A Mantalaris","year":"2001","unstructured":"Mantalaris A et al (2001) Localization of androgen receptor expression in human bone marrow. J Pathol 193(3):361\u2013366","journal-title":"J Pathol"},{"issue":"7","key":"10365_CR30","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/S0046-8177(03)00190-4","volume":"34","author":"MP Roudier","year":"2003","unstructured":"Roudier MP et al (2003) Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol 34(7):646\u2013653","journal-title":"Hum Pathol"},{"issue":"6","key":"10365_CR31","doi-asserted-by":"publisher","first-page":"R187","DOI":"10.1530\/ERC-12-0085","volume":"19","author":"DA Barron","year":"2012","unstructured":"Barron DA, Rowley DR (2012) The reactive stroma microenvironment and prostate cancer progression. Endocr-Relat Cancer 19(6):R187\u2013R204","journal-title":"Endocr-Relat Cancer"},{"key":"10365_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.diff.2018.09.002","volume":"103","author":"GR Cunha","year":"2018","unstructured":"Cunha GR, Baskin L (2018) Development of human male and female urogenital tracts. Differentiation 103:1\u20134","journal-title":"Differentiation"},{"issue":"8","key":"10365_CR33","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1242\/dev.148270","volume":"144","author":"R Toivanen","year":"2017","unstructured":"Toivanen R, Shen MM (2017) Prostate organogenesis: tissue induction, hormonal regulation and cell type specification. Development 144(8):1382\u20131398","journal-title":"Development"},{"issue":"1","key":"10365_CR34","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/s41467-017-00460-4","volume":"8","author":"S Tyekucheva","year":"2017","unstructured":"Tyekucheva S et al (2017) Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. Nat Commun 8(1):420","journal-title":"Nat Commun"},{"issue":"8","key":"10365_CR35","doi-asserted-by":"publisher","first-page":"R146","DOI":"10.1530\/EC-17-0118","volume":"6","author":"E Jernberg","year":"2017","unstructured":"Jernberg E, Bergh A, Wikstrom P (2017) Clinical relevance of androgen receptor alterations in prostate cancer. Endocr Connect 6(8):R146\u2013R61","journal-title":"Endocr Connect"},{"issue":"8","key":"10365_CR36","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1002\/pros.20927","volume":"69","author":"P Wikstrom","year":"2009","unstructured":"Wikstrom P et al (2009) Low stroma androgen receptor level in normal and tumor prostate tissue is related to poor outcome in prostate cancer patients. Prostate 69(8):799\u2013809","journal-title":"Prostate"},{"issue":"3\u20134","key":"10365_CR37","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1007\/s10585-017-9848-8","volume":"34","author":"A Nordstrand","year":"2017","unstructured":"Nordstrand A et al (2017) Inhibition of the insulin-like growth factor-1 receptor potentiates acute effects of castration in a rat model for prostate cancer growth in bone. Clin Exp Metastasis 34(3\u20134):261\u2013271","journal-title":"Clin Exp Metastasis"},{"issue":"2","key":"10365_CR38","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/s41556-018-0267-0","volume":"21","author":"P Carlson","year":"2019","unstructured":"Carlson P et al (2019) Targeting the perivascular niche sensitizes disseminated tumour cells to chemotherapy. Nat Cell Biol 21(2):238\u2013250","journal-title":"Nat Cell Biol"},{"issue":"7","key":"10365_CR39","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1038\/ncb2767","volume":"15","author":"CM Ghajar","year":"2013","unstructured":"Ghajar CM et al (2013) The perivascular niche regulates breast tumour dormancy. Nat Cell Biol 15(7):807\u2013817","journal-title":"Nat Cell Biol"},{"key":"10365_CR40","doi-asserted-by":"crossref","unstructured":"Graham N, Qian BZ (2018) Mesenchymal stromal cells: emerging roles in bone metastasis. Int J Mol Sci 19:4","DOI":"10.3390\/ijms19041121"},{"issue":"5","key":"10365_CR41","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nrc.2017.6","volume":"17","author":"H Peinado","year":"2017","unstructured":"Peinado H et al (2017) Pre-metastatic niches: organ-specific homes for metastases. Nat Rev Cancer 17(5):302\u2013317","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10365_CR42","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1038\/s41568-021-00406-5","volume":"22","author":"RL Satcher","year":"2022","unstructured":"Satcher RL, Zhang XH (2022) Evolving cancer-niche interactions and therapeutic targets during bone metastasis. Nat Rev Cancer 22(2):85\u2013101","journal-title":"Nat Rev Cancer"},{"issue":"27","key":"10365_CR43","doi-asserted-by":"publisher","first-page":"41217","DOI":"10.18632\/oncotarget.9251","volume":"7","author":"Y Shiozawa","year":"2016","unstructured":"Shiozawa Y et al (2016) The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget 7(27):41217\u201341232","journal-title":"Oncotarget"},{"issue":"1","key":"10365_CR44","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.ajur.2018.11.003","volume":"6","author":"GC Chu","year":"2019","unstructured":"Chu GC et al (2019) Regulatory signaling network in the tumor microenvironment of prostate cancer bone and visceral organ metastases and the development of novel therapeutics. Asian J Urol 6(1):65\u201381","journal-title":"Asian J Urol"},{"key":"10365_CR45","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.urology.2015.12.039","volume":"92","author":"J Hensel","year":"2016","unstructured":"Hensel J, Thalmann GN (2016) Biology of bone metastases in prostate Cancer. Urology 92:6\u201313","journal-title":"Urology"},{"issue":"11","key":"10365_CR46","doi-asserted-by":"publisher","first-page":"1203","DOI":"10.1007\/s00109-015-1329-4","volume":"93","author":"G Ren","year":"2015","unstructured":"Ren G, Esposito M, Kang Y (2015) Bone metastasis and the metastatic niche. J Mol Med (Berl) 93(11):1203\u20131212","journal-title":"J Mol Med (Berl)"},{"issue":"1","key":"10365_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1158\/0008-5472.CAN-16-3507","volume":"78","author":"S Rossnagl","year":"2018","unstructured":"Rossnagl S et al (2018) A subpopulation of stromal cells controls Cancer cell homing to the bone marrow. Cancer Res 78(1):129\u2013142","journal-title":"Cancer Res"},{"issue":"3","key":"10365_CR48","doi-asserted-by":"publisher","first-page":"e10126","DOI":"10.1002\/jbm4.10126","volume":"3","author":"ME Sowder","year":"2019","unstructured":"Sowder ME, Johnson RW (2019) Bone as a preferential site for metastasis. JBMR Plus 3(3):e10126","journal-title":"JBMR Plus"},{"key":"10365_CR49","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1101\/sqb.2016.81.030775","volume":"81","author":"H Zheng","year":"2016","unstructured":"Zheng H, Li W, Kang Y (2016) Tumor-Stroma interactions in bone metastasis: molecular mechanisms and therapeutic implications. Cold Spring Harb Symp Quant Biol 81:151\u2013161","journal-title":"Cold Spring Harb Symp Quant Biol"},{"key":"10365_CR50","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ctrv.2019.05.003","volume":"76","author":"R von Moos","year":"2019","unstructured":"von Moos R et al (2019) Management of bone health in solid tumours: from bisphosphonates to a monoclonal antibody. Cancer Treat Rev 76:57\u201367","journal-title":"Cancer Treat Rev"},{"issue":"4","key":"10365_CR51","doi-asserted-by":"publisher","first-page":"238","DOI":"10.1038\/nrc3910","volume":"15","author":"CM Ghajar","year":"2015","unstructured":"Ghajar CM (2015) Metastasis prevention by targeting the dormant niche. Nat Rev Cancer 15(4):238\u2013247","journal-title":"Nat Rev Cancer"},{"issue":"2","key":"10365_CR52","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1210\/endo.139.2.5683","volume":"139","author":"I Franck-Lissbrant","year":"1998","unstructured":"Franck-Lissbrant I et al (1998) Testosterone stimulates angiogenesis and vascular regrowth in the ventral prostate in castrated adult rats. Endocrinology 139(2):451\u2013456","journal-title":"Endocrinology"},{"issue":"1","key":"10365_CR53","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1002\/pros.10312","volume":"58","author":"IF Lissbrant","year":"2004","unstructured":"Lissbrant IF et al (2004) Neutralizing VEGF bioactivity with a soluble chimeric VEGF-receptor protein flt(1\u20133)IgG inhibits testosterone-stimulated prostate growth in castrated mice. Prostate 58(1):57\u201365","journal-title":"Prostate"},{"key":"10365_CR54","first-page":"1","volume":"13","author":"HB Song","year":"2022","unstructured":"Song HB et al (2022) Single-cell analysis of human primary prostate cancer reveals the heterogeneity of tumor-associated epithelial cell States. Nat Commun 13:1","journal-title":"Nat Commun"},{"issue":"2","key":"10365_CR55","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1002\/pros.23929","volume":"80","author":"RE Vickman","year":"2020","unstructured":"Vickman RE et al (2020) Heterogeneity of human prostate carcinoma-associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment. Prostate 80(2):173\u2013185","journal-title":"Prostate"},{"issue":"1","key":"10365_CR56","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s11658-023-00450-z","volume":"28","author":"X Yu","year":"2023","unstructured":"Yu X et al (2023) Single-cell omics traces the heterogeneity of prostate cancer cells and the tumor microenvironment. Cell Mol Biol Lett 28(1):38","journal-title":"Cell Mol Biol Lett"},{"issue":"4","key":"10365_CR57","doi-asserted-by":"publisher","first-page":"e1214771","DOI":"10.1080\/23723556.2016.1214771","volume":"4","author":"TT Price","year":"2017","unstructured":"Price TT, Sipkins DA (2017) E-Selectin and SDF-1 regulate metastatic trafficking of breast cancer cells within the bone. Mol Cell Oncol 4(4):e1214771","journal-title":"Mol Cell Oncol"},{"issue":"6","key":"10365_CR58","doi-asserted-by":"publisher","first-page":"e1257","DOI":"10.1016\/j.clgc.2018.07.019","volume":"16","author":"C Cattrini","year":"2018","unstructured":"Cattrini C et al (2018) Overexpression of Periostin in tumor biopsy samples is associated with prostate Cancer phenotype and clinical outcome. Clin Genitourin Cancer 16(6):e1257\u2013e65","journal-title":"Clin Genitourin Cancer"},{"issue":"3","key":"10365_CR59","doi-asserted-by":"publisher","first-page":"e0121502","DOI":"10.1371\/journal.pone.0121502","volume":"10","author":"Y Tian","year":"2015","unstructured":"Tian Y et al (2015) Overexpression of periostin in stroma positively associated with aggressive prostate cancer. PLoS ONE 10(3):e0121502","journal-title":"PLoS ONE"},{"issue":"4","key":"10365_CR60","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1038\/nrurol.2012.19","volume":"9","author":"IJ Edwards","year":"2012","unstructured":"Edwards IJ (2012) Proteoglycans in prostate cancer. Nat Rev Urol 9(4):196\u2013206","journal-title":"Nat Rev Urol"},{"issue":"8","key":"10365_CR61","doi-asserted-by":"publisher","first-page":"e42516","DOI":"10.1371\/journal.pone.0042516","volume":"7","author":"A Henke","year":"2012","unstructured":"Henke A et al (2012) Stromal expression of decorin, Semaphorin6D, SPARC, Sprouty1 and Tsukushi in developing prostate and decreased levels of decorin in prostate cancer. PLoS ONE 7(8):e42516","journal-title":"PLoS ONE"},{"issue":"5","key":"10365_CR62","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1002\/dvdy.24619","volume":"247","author":"M Montano","year":"2018","unstructured":"Montano M et al (2018) Dual regulation of decorin by androgen and Hedgehog signaling during prostate morphogenesis. Dev Dyn 247(5):679\u2013685","journal-title":"Dev Dyn"},{"issue":"10","key":"10365_CR63","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1593\/neo.09760","volume":"11","author":"Y Hu","year":"2009","unstructured":"Hu Y et al (2009) Decorin suppresses prostate tumor growth through Inhibition of epidermal growth factor and androgen receptor pathways. Neoplasia 11(10):1042\u20131053","journal-title":"Neoplasia"},{"key":"10365_CR64","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.addr.2015.10.016","volume":"97","author":"T Neill","year":"2016","unstructured":"Neill T, Schaefer L, Iozzo RV (2016) Decorin as a multivalent therapeutic agent against cancer. Adv Drug Deliv Rev 97:174\u2013185","journal-title":"Adv Drug Deliv Rev"},{"key":"10365_CR65","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.matbio.2015.01.023","volume":"43","author":"H Jarvelainen","year":"2015","unstructured":"Jarvelainen H, Sainio A, Wight TN (2015) Pivotal role for decorin in angiogenesis. Matrix Biol 43:15\u201326","journal-title":"Matrix Biol"},{"key":"10365_CR66","doi-asserted-by":"crossref","unstructured":"Jarvinen TA, Prince S (2015) Decorin: a growth factor antagonist for tumor growth inhibition. Biomed Res Int 2015:654765","DOI":"10.1155\/2015\/654765"},{"issue":"3","key":"10365_CR67","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1038\/gt.2014.110","volume":"22","author":"W Xu","year":"2015","unstructured":"Xu W et al (2015) The systemic delivery of an oncolytic adenovirus expressing decorin inhibits bone metastasis in a mouse model of human prostate cancer. Gene Ther 22(3):247\u2013256","journal-title":"Gene Ther"},{"issue":"7286","key":"10365_CR68","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1038\/nature08782","volume":"464","author":"M Ammirante","year":"2010","unstructured":"Ammirante M et al (2010) B-cell-derived lymphotoxin promotes castration-resistant prostate cancer. Nature 464(7286):302\u2013305","journal-title":"Nature"},{"key":"10365_CR69","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3390\/ijms24076302","volume":"24","author":"F Sciarra","year":"2023","unstructured":"Sciarra F et al (2023) Gender-specific impact of sex hormones on the immune system. Int J Mol Sci 24:7","journal-title":"Int J Mol Sci"},{"issue":"3","key":"10365_CR70","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1016\/j.cell.2005.12.032","volume":"124","author":"P Zhu","year":"2006","unstructured":"Zhu P et al (2006) Macrophage\/cancer cell interactions mediate hormone resistance by a nuclear receptor derepression pathway. Cell 124(3):615\u2013629","journal-title":"Cell"},{"issue":"1","key":"10365_CR71","doi-asserted-by":"publisher","first-page":"2419","DOI":"10.1038\/s41467-018-04724-5","volume":"9","author":"E Berglund","year":"2018","unstructured":"Berglund E et al (2018) Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity. Nat Commun 9(1):2419","journal-title":"Nat Commun"},{"key":"10365_CR72","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41556-020-00613-6","volume":"23","author":"SJ Chen","year":"2021","unstructured":"Chen SJ et al (2021) Single-cell analysis reveals transcriptomic remodellings in distinct cell types that contribute to human prostate cancer progression. Nat Cell Biol 23:1","journal-title":"Nat Cell Biol"},{"issue":"1","key":"10365_CR73","doi-asserted-by":"publisher","first-page":"5475","DOI":"10.1038\/s41467-022-33069-3","volume":"13","author":"M Marklund","year":"2022","unstructured":"Marklund M et al (2022) Spatio-temporal analysis of prostate tumors in situ suggests pre-existence of treatment-resistant clones. Nat Commun 13(1):5475","journal-title":"Nat Commun"},{"key":"10365_CR74","doi-asserted-by":"crossref","unstructured":"MacDonald WJ et al (2025) Heterogeneity in cancer. Cancers (Basel) 173","DOI":"10.3390\/cancers17030441"}],"container-title":["Clinical &amp; Experimental Metastasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10585-025-10365-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10585-025-10365-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T06:04:33Z","timestamp":1760076273000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10585-025-10365-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,21]]},"references-count":74,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["10365"],"URL":"https:\/\/doi.org\/10.1007\/s10585-025-10365-y","relation":{},"ISSN":["1573-7276"],"issn-type":[{"value":"1573-7276","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,21]]},"assertion":[{"value":"10 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"A.B., E.T., and P.W. have a pending patent application related to the metastasis subtypes MetA-C and to Ki67 and PSA immunostaining as surrogate markers for the molecular metastasis subtypes (\u2018Methods for diagnosis and prognosis of prostate cancer\u2019, EP2020\/054681).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"49"}}